This site is intended for US healthcare professionals only

For Patients and Caregivers
Important Safety Information
Prescribing Information
SIGN UP

Search

Mechanism of action
Steps to treatment
- Before treatmentIdentifying eligible patients
- Dosing and infusionGetting ready for infusion day
- After treatmentEssential post-infusion monitoring and management
Clinical Experiences
- STR1VE trial
- START trial
- START long-term follow-up
- SPR1NT trial
- SafetyView Important Safety Information
Patient Profiles
- Commercial patient stories
- START patient stories
Understand SMA
Resources

SIGN UP

Search

Mechanism of action
Steps to treatment
- Before treatmentIdentifying eligible patients
- Dosing and infusionGetting ready for infusion day
- After treatmentEssential post-infusion monitoring and management
Clinical Experiences
- STR1VE trial
- START trial
- START long-term follow-up
- SPR1NT trial
- SafetyView Important Safety Information
Patient Profiles
- Commercial patient stories
- START patient stories
Understand SMA
Resources

For Patients and Caregivers

Site map

Mechanism of action
Steps to treatment
- Before treatmentIdentifying eligible patients
- Dosing and infusionGetting ready for infusion day
- After treatmentEssential post-infusion monitoring and management
Clinical Experiences
- STR1VE trial
- START trial
- START long-term follow-up
- SPR1NT trial
- SafetyView Important Safety Information
Patient Profiles
- Commercial patient stories
- START patient stories
Understand SMA
Resources

Important Safety Information

BOXED WARNING: Serious Liver Injury and Acute Liver Failure

Cases of acute liver failure with fatal outcomes have been reported. Acute serious liver injury, acute liver failure, and elevated aminotransferases can also occur with ZOLGENSMA. Patients with preexisting liver impairment may be at higher risk. Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing. Administer

Indication

ZOLGENSMA is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Limitations of Use

The safety and effectiveness of repeat administration or the use in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been evaluated with ZOLGENSMA.

Important Safety Information

BOXED WARNING: Serious Liver Injury and Acute Liver Failure

Cases of acute liver failure with fatal outcomes have been reported. Acute serious liver injury, acute liver failure, and elevated aminotransferases can also occur with ZOLGENSMA. Patients with preexisting liver impairment may be at higher risk. Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing. Administer systemic corticosteroid to all patients before and after ZOLGENSMA infusion. Continue to monitor liver function for at least 3 months after infusion, and at other times as clinically indicated. If acute serious liver injury or acute liver failure is suspected, promptly consult a pediatric gastroenterologist or hepatologist.

WARNINGS AND PRECAUTIONS

Systemic Immune Response

Patients with underlying active infection, either acute or chronic uncontrolled, could be at an increased risk of serious systemic immune response. Administer ZOLGENSMA to patients who are clinically stable in their overall health status (e.g., hydration and nutritional status, absence of infection). Postpone ZOLGENSMA in patients with infections until the infection has resolved and the patient is clinically stable.

Thrombocytopenia

Transient decreases in platelet counts, some of which met the criteria for thrombocytopenia, were typically observed within the first two weeks after ZOLGENSMA infusion. Monitor platelet counts before ZOLGENSMA infusion and on a regular basis for at least 3 months afterwards.

Thrombotic Microangiopathy

Cases of thrombotic microangiopathy (TMA) were reported to occur generally within the first two weeks after ZOLGENSMA infusion. TMA can result in life-threatening or fatal outcomes. Obtain baseline creatinine and complete blood count before ZOLGENSMA infusion. Following infusion, monitor platelet counts closely as well as other signs and symptoms of TMA. Consult a pediatric hematologist and/or pediatric nephrologist immediately to manage as clinically indicated.

Elevated Troponin-I

Increases in cardiac troponin-I levels were observed following ZOLGENSMA infusion. Monitor troponin-I before ZOLGENSMA infusion and on a regular basis for at least 3 months afterwards. Consider consultation with a cardiologist if troponin elevations are accompanied by clinical signs or symptoms.

ADVERSE REACTIONS

The most commonly observed adverse reactions (incidence ≥5%) in clinical studies were elevated aminotransferases and vomiting.

Please click here for Full Prescribing Information.

PRIVACY POLICY
TERMS OF USE
SITE MAP
CONTACT US

This website may use cookies to improve the site and your experience. See how Novartis Gene Therapies collects, uses, and shares your personal information in our Privacy Policy.

This site is intended for US healthcare professionals only.

© 2023 Novartis Gene Therapies, Inc.
Bannockburn, IL 60015

03/2023 US-ZOL-20-0069 V12

You are now leaving
ZOLGENSMA-hcp.com:

Novartis Gene Therapies provides links to third-party sites as a convenience and is not responsible for the content of these sites.

Would you like to continue?
Click "No" to keep browsing ZOLGENSMA-hcp.com.

Yes